The Pathological Study On Expression Of CK19, Vimentin, VEGF, COX-2, VEGF-C And The Detection Of ER And PR MRNA In PTC

Objectives and Methods:PTC and FTC is the follicular-derived carcinoma,According to lymph node metastasis and differentiation, PTC were divided into two groups, FTC is divided into well differentiated type and poorly differentiated type. Home and abroad literature reported that CK19, Vimentin, VEGF, VEGF-C, COX-2 had relationship with PTC and FTC of the diagnosis, differential diagnosis, metastasis, differentiation.We detected the five indicators expression in PTC and FTC with the immunohistochemical method.By analyzing the five indicators expression,we find the relationship with PTC and FTC of the diagnosis, differential diagnosis, metastasis, differentiation.χ2 test is used to compare the positive rate of the two independent sample rate, Spearman correlation coefficient non-parametric test is used to Rank the relevance of two information, Wilcoxon test was used rating data, two independent samples t-test was used to compare the age of PTC and FTC.The aim of our study in part two was to ascertain the relationship of estrogen receptor and progesterone receptor with thyroid papillary carcinoma in the pathogenesis, diagnosis, treatment and clinical diagnosis, providing a theoretical basis.ER, PR results use the completely randomized design analysis of variance under the quantitative data. RT-PCR and SYBR Green QRT-PCR were used to test the ER, PR two kinds of genes in qualitative and quantitative view.Results:1.PTC, FTC gender (female/male) ratios were 3.27/1,3.15/1, PTC and FTC sex ratio showed no significant difference,χ2=0.009 (P> 0.05); PTC, FTC average diagnosed aged 41.86,41.65 (years) showed no significant difference (t=0.085, P>0.05), PTC diagnosed male average age (47.68 years) was older than in females diagnosis average age (40.08 years),t=2.313, P<0.05.FTC well-differentiated type average age (37.22 years) was younger than in poorly differentiated type (46.07 years), t=-2.043, (P<0.05).2. CK19 mainly expressed in the cytoplasm of cancer cells. CK19 positive rate (91.43%) in metastatic PTC was bigger than primary tumors (89.83%), CK19 positive rate (74.07%) in well differentiated type FTC was bigger than in poorly differentiated type (48.15%),(P> 0.05). CK19 total positive rate (90.43%) in PTC was bigger than in FTC (61.11%), (P<0.05).3.Vimentin-positive material is mainly distributed in the cytoplasm of cancer cells and stromal cells showed positive staining.Vimentin positive rate is 100% in all caes.strong positive rates were 50.00%,16.67%, PTC strong expression group was higher than FTC,Vimentin expression intensity in PTC metastasis was higher than the primary tumor,Vimentin expression intensity in FTC well-differentiated type was higher than in poorly differentiated type, by rank sum test with statistical significance (P<0.05).4.VEGF-C was mainly expressed in the cytoplasm of cancer cells, VEGF-C positive rate (88.57%) in metastatic PTC was higher than in primary tumors (84.75%), VEGF-C positive rate (88.89%) in FTC well differentiated type was higher than in poorly differentiated type (85.19%), VEGF-C general positive rate in PTC and FTC was 86.17%,87.04%(P>0.05). VEGF-C in PTC strongly positive rate (24.69%) was higher than in FTC (8.51%) (P<0.05).5. COX-2 was mainly expressed in the cytoplasm of cancer cells. COX-2 positive rate (82.86%) in the metastatic PTC was higher than primary tumors (81.36%), well differentiated FTC type (85.19%) was higher than in poorly differentiated type (77.78%), General COX-2 expression rate in PTC and FTC was 81.91%,91.48%, no significant difference (P>0.05).6. VEGF was mainly expressed in the cytoplasm of cancer cells. VEGF positive rate of metastasis PTC (92.50%) was higher than primary tumors (90.00%), FTC in the poorly differentiated type group (92.86%) was higher than in well-type group (87.10%), PTC group (91.25%) was higher than in FTC (89.83%), no significant difference between the three groups (P>0.05).7.90.43% of PTC of the expression of CK19 and Vimentin were consistent (both positive or both negative), through the Spearman rank correlation analysis, r= 0.188 (P>0.05). only 61.11% percent of the expression of CK19 and Vimentin in FTC were consistent, through Spearman rank correlation analysis, r=0.228 (P>0.05). 95.74% of the VEGF-C and COX-2 expression in PTC were consistent (both positive or both negative), r=0.438(P<0.05).VEGF-C and COX-2 immune strength show weak positive> moderately positive> strong positive in primary lesions and metastasis in PTC, FTC well-differentiated type, poorly differentiated type group.But VEGF-C in primary PTC and COX-2 in metastatic FTC showed moderately positive>weak positive>strongly positive.8. The highest sensitivity in the four indicators is Vimentin (100.00%).9. RT-PCR results showed that in 5 cases of nodular goiter, there are four cases of ER-positive bands in the 100～250 bp region, the positive rate was 80%, PR has no positive bands.10. RT-PCR results showed that PTC 7 specimens in 1 case with ER-positive bands in the 100～250 bp region, the positive rate was 14%, PR positive bands were not seen.11. RT-PCR results showed that HT 2 specimens can be seen in ER-positive bands in the 100～250 bp region,are no PR-positive bands.12. Real-time quantitative PCR results showed that three kinds of diseases have no difference between the expression of ER.Conclusion:1.The average age of the PTC and FTC (41.86 years,41.65 years) was no significant difference, PTC diagnosed male average age (47.68 years) was higher than in females diagnosis average age (40.08 years), FTC average well-differentiated type diagnosis of age (37.22 years) was lower than in poorly differentiated type (46.07 years), there was significant (P<0.05).2.CK19 total positive rate in PTC(90.43%)was higher than in follicular carcinoma (61.11%),has statistically significant (P<0.05). Suggesting that CK19 can be used to identificate the PTC and FTC.Strong positive rate in PTC(51.76%) was higher than in FTC(27.27%), Vimentin positive rate in PTC metastasis was higher than the primary tumor, Intensity positive expression of Vimentin in FTC well differentiated type was higher than poorly differentiated types, there was significant (P<0.05). Suggesting that Vimentin can be used to identificate PTC and FTC.VEGF-C expression in PTC group was higher than FTC group expression, VEGF-C expression in PTC was higher than in FTC (P<0.05), the different expression intensity in PTC and FTC can provide the basis for identification.3. CK19 and Vimentin had no correlation in PTC and FTC. VEGF-C and COX-2 was directly proportional to the degree of differentiation and a positive correlation between the two indicators of trends, VEGF-C and COX-2 expression was positively correlated in PTC. The two indexes have a positive correlation trend. Through the Spearman rank correlation analysis, both in papillary carcinoma was positively correlated,r=0.438, P<0.05. VEGF-C and COX-2 immune strength show weak positive>moderately positive>strong positive in primary lesions in PTC, metastasis, FTC well-differentiated type and poorly differentiated type group,but VEGF-C in primary tumors PTC and COX-2 in metastatic FTC showed moderately positive> weak positive> strongly positive. Suggesting that VEGF-C and COX-2 had mutually reinforcing roles in development, invasion and metastasis.4.Comprehensive testing CK19, Vimentin, VEGF, VEGF-C and COX-2 expression in follicular thyroid cancer diagnosis, differential diagnosis, differentiation, tumor metastasis and prognosis of trends has some reference value.5.Benign and malignant thyroid diseases can be detected in ER, the highest bridge nature of thyroiditis, papillary carcinoma of the second, a minimum of nodular goiter, indicating estrogen in the occurrence and development of thyroid disease play a role in real-time quantitative results showed that three kinds of diseases, no statistically significant difference between, suggesting that estrogen may play a role in thyroid diseases indirect effects. Papillary thyroid carcinoma is considered to be hormone-dependent tumors, ER testing for thyroid disease diagnosis and therapy. Hormone therapy for thyroid disease provided the basis.